Second-site suppressor mutations reveal connection between the drug-binding pocket and nucleotide-binding domain 1 of human P-glycoprotein (ABCB1)

被引:5
|
作者
Murakami, Megumi [1 ]
Sajid, Andaleeb [1 ]
Lusvarghi, Sabrina [1 ]
Durell, Stewart R. [1 ]
Abel, Biebele [1 ]
Vahedi, Shahrooz [1 ]
Golin, John [2 ]
Ambudkar, Suresh V. [3 ]
机构
[1] NCI, NIH, Ctr Canc Res, Lab Cell Biol, Bethesda, MD 20892 USA
[2] Catholic Univ Amer, Dept Biol, Washington, DC 20064 USA
[3] NCI, Cell Biol Lab, Ctr Canc Res, NIH, 37 Convent Dr,Room 2120, Bethesda, MD 20892 USA
基金
美国国家卫生研究院; 日本学术振兴会;
关键词
ABC transporter; Multidrug resistance; P-glycoprotein; Second -site suppressors; Molecular dynamics simulations; MULTIDRUG-RESISTANCE; ATP HYDROLYSIS; CATALYTIC CYCLE; TRANSPORT; EXPRESSION; INHIBITION; SUBSTRATE; TRANSLOCATION; MODULATION; INTERFACE;
D O I
10.1016/j.drup.2023.101009
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Human P-glycoprotein (P-gp) or ABCB1 is overexpressed in many cancers and has been implicated in altering the bioavailability of chemotherapeutic drugs due to their efflux, resulting in the development of chemoresistance. To elucidate the mechanistic aspects and structure-function relationships of P-gp, we previously utilized a tyrosine (Y)-enriched P-gp mutant (15Y) and demonstrated that at least 15 conserved residues in the drug -binding pocket of P-gp are responsible for optimal substrate interaction and transport. To further understand the role of these 15 residues, two new mutants were generated, namely 6Y with the substitution of six residues (F72, F303, I306, F314, F336 and L339) with Y in transmembrane domain (TMD) 1 and 9Y with nine sub-stitutions (F732, F759, F770, F938, F942, M949, L975, F983 and F994) in TMD2. Although both the mutants were expressed at normal levels at the cell surface, the 6Y mutant failed to transport all the tested substrates except Bodipy-verapamil, whereas the 9Y mutant effluxed all tested substrates in a manner very similar to that of the wild-type protein. Further mutational analysis revealed that two second-site mutations, one in intracellular helix (ICH) 4 (F916Y) and one in the Q loop of nucleotide-binding domain (NBD) 1 (F480Y) restored the transport function of 6Y. Additional biochemical data and comparative molecular dynamics simulations of the 6Y and 6Y+F916Y mutant indicate that the Q-loop of NBD1 of P-gp communicates with the substrate-binding sites in the transmembrane region through ICH4.This is the first evidence for the existence of second-site suppressors in human P-gp that allow recovery of the loss of transport function caused by primary mutations. Further study of such mutations could facilitate mapping of the communication pathway between the substrate-binding pocket and the NBDs of P-gp and possibly other ABC drug transporters.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Catalytic Transitions in the Human MDR1 P-Glycoprotein Drug Binding Sites
    Wise, John G.
    BIOCHEMISTRY, 2012, 51 (25) : 5125 - 5141
  • [42] Association between 8 P-glycoprotein (MDR1/ABCB1) gene polymorphisms and antipsychotic drug-induced hyperprolactinaemia
    Geers, Lisanne M.
    Pozhidaev, Ivan, V
    Ivanova, Svetlana A.
    Freidin, Maxim B.
    Schmidt, Amand F.
    Cohen, Dan
    Boiko, Anastasiia S.
    Paderina, Diana Z.
    Fedorenko, Olga Yu
    Semke, Arkadiy, V
    Bokhan, Nikolay A.
    Wilffert, Bob
    Kosterink, Jos G. W.
    Touw, Daan J.
    Loonen, Anton J. M.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 86 (09) : 1827 - 1835
  • [43] Mechanism of polyspecificity of P-glycoprotein: Substitution of fifteen residues in the drug-binding pocket with tyrosine reveals a negative correlation between substrate size and transport
    Vahedi, Shahrooz
    Chufan, Eduardo
    Ambudkar, Suresh V.
    CANCER RESEARCH, 2017, 77
  • [44] Nucleotide triphosphatase activity of the N-terminal nucleotide-binding domains of the multidrug resistance proteins P-glycoprotein and MRP1
    Wilkes, DM
    Wang, CS
    Aristimuño, PC
    Castro, AF
    Altenberg, GA
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 296 (02) : 388 - 394
  • [45] Processing mutations located throughout the human multidrug resistance P-glycoprotein disrupt interactions between the nucleotide binding domains
    Loo, TW
    Bartlett, MC
    Clarke, DM
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (37) : 38395 - 38401
  • [46] Mutational analysis reveals the importance of residues of the access tunnel inhibitor site to human P-glycoprotein (ABCB1)-mediated transport
    Salazar, Paula B.
    Murakami, Megumi
    Ranganathan, Nandhini
    Durell, Stewart R.
    Ambudkar, Suresh V.
    PROTEIN SCIENCE, 2024, 33 (09)
  • [47] Identification of residues within the drug-binding domain of the human multidrug resistance P-glycoprotein by cysteine-scanning mutagenesis and reaction with dibromobimane
    Loo, TW
    Clarke, DM
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (50) : 39272 - 39278
  • [48] Promoter Haplotypes of the ABCB1 Gene Encoding the P-Glycoprotein Differentially Affect Its Promoter Activity by Altering Transcription Factor Binding
    Speidel, Jordan T.
    Xu, Meixiang
    Abdel-Rahman, Sherif Z.
    DNA AND CELL BIOLOGY, 2018, 37 (12) : 973 - 981
  • [49] Cysteines 431 and 1074 are responsible for inhibitory disulfide cross-linking between the two nucleotide-binding sites in human P-glycoprotein
    Urbatsch, IL
    Gimi, K
    Wilke-Mounts, S
    Lerner-Marmarosh, N
    Rousseau, ME
    Gros, P
    Senior, AE
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (29) : 26980 - 26987
  • [50] RELATIONSHIP BETWEEN CHEMICAL MOIETIES AND HUMAN ABC TRANSPORTER ABCB1 (P-GLYCOPROTEIN/MDR1) POLYMORPHISMS IN DRUG-INDUCED LIVER INJURY (DILI)
    Ulzurrun, E.
    Crespo, E.
    Ruiz-Cabello, F.
    Stephens, C.
    Borraz, Y.
    Robles, M.
    Cabello, M. R.
    Fernandez, M. C.
    Moreno-Herrera, I.
    Romero-Gomez, M.
    Navarro, J. M.
    Planas, R.
    Guarner, C.
    Castiella, A.
    Lucena, M. I.
    Andrade, R. J.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2011, 109 : 43 - 44